First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most-but not all-subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-08-13
DOI
https://doi.org/10.1200/jco.24.01125
Citations
47
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
13.28
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Hussein A. Tawbi, Evan J. Lipson, Laura McDonald, Paolo A. Ascierto et al.
47 citations
Journal of Clinical Oncology
CAR-T cell therapy research
13.28
article

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Hussein A. Tawbi, Evan J. Lipson, Laura McDonald, Paolo A. Ascierto, Flavia Ejzykowicz, Dirk Schadendorf, Andriy Moshyk, Jennell Palaia, Viviana García-Horton, Anthony Salvatore, Jean‐Jacques Grob, Georgina Venetia Long, James Larkin, Sarah Keidel, F. Stephen Hodi, Leon A. Sakkal, Yiqiao Xin, Divya Patel, Zheng‐Yi Zhou, Christopher D. Lao
article en
47 citations

Abstract

Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most-but not all-subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.

Journal of Clinical OncologyVol. 42(33)
The University of Sydney (AU), Royal Marsden NHS Foundation Trust (GB), The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), Aix-Marseille Université (FR), University of Michigan (US), Bristol-Myers Squibb (United States) (US), National Center for Tumor Diseases (DE), Dana-Farber Cancer Institute (US), Melanoma Institute Australia (AU), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Hôpital de la Timone (FR), Sidney Kimmel Comprehensive Cancer Center (US), Deutsches Konsortium für Translationale Krebsforschung (DE), Analysis Group (United States) (US)
Good health and well-being
Openalex Percentile: Top 1%
CAR-T cell therapy research
13.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.